Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10390555 | 0.90 | POLB (0.47) | CA1CA2CA9POLBALDH1A1 | |
| SCHEMBL6589802 | 0.89 | CA1 (0.66) | CA1CA2CA9POLBCA12 | |
| SCHEMBL10390178 | 0.88 | TDP1 (0.47) | CA1CA2CA9POLBALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28745712 | 0.87 | CA1 (0.63) | CA1CA2CA9POLBCA12 | |
| SCHEMBL12013298 | 0.86 | TSHR (0.48) | CA1CA2CA9ALDH1A1LMNA | |
| SCHEMBL30388469 | 0.86 | TSHR (0.48) | CA1CA2CA9ALDH1A1LMNA | |
| SCHEMBL25622617 | 0.86 | TSHR (0.48) | CA1CA2CA9ALDH1A1LMNA | |
| SCHEMBL10316643 | 0.86 | TSHR (0.48) | CA1CA2CA9ALDH1A1LMNA | |
| SCHEMBL6379981 | 0.86 | TSHR (0.48) | CA1CA2CA9ALDH1A1LMNA | |
| SCHEMBL10792367 | 0.84 | KCNH2 (0.45) | CA1CA2CA9CA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-5166218-A | Antilipemic agents or antiglycemic agents | HOFFMANN-LA ROCHE INC. (US) | 1992-11-24 | — | — | US | disclosed |
| US-5064863-A | Catabolic activity, obesity, diabetes | HOFFMANN-LA ROCHE INC. (US) | 1991-11-12 | — | — | US | disclosed |
| US-4988714-A | Drugs for treatment of obesity and diabetics, increases protein breakdown, for fattening animals | HOFFMANN-LA ROCHE INC. (US) | 1991-01-29 | — | — | US | disclosed |
| US-4800206-A | ANTIDIABETIC AGENTS; HYPOGLYCEMIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1989-01-24 | — | — | US | disclosed |
| US-4649160-A | HYPOTENSIVE, ANTIARRHYTHMIA, ADRENERGIC BLOCKING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1987-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | CA1 124/4885CA2 1585/4885CA9 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.